A kind of synthetic method of Duvelisib
Through the six-step synthesis route, gentle reaction conditions and easy-to-get raw materials are used to solve the problems of harsh reaction conditions and low yields in the existing duvelisibu synthesis, and achieve high yield and high purity duvelisi Cloth synthesis, suitable for industrial production.
Patent Information
- Application Number
- CN202410608374.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-05-16
AI Technical Summary
The existing duvelisibu synthesis method uses expensive and flammable n-butyllithium, with harsh reaction conditions, low yield, low stereoselectivity, rare raw materials, unfriendly environment, affecting industrial production.
Through six steps of synthesis route: Compound 2 condensation with dimethyl oxalate, ester hydrolysis, condensation reaction, addition dehydration, reduction reaction, hydrolysis, and amine hydrocarbonization, finally obtain duvelisib, using mild reaction conditions, using Easy-to-get raw materials improve the yield and purity of each step of the reaction.
The synthesis of Duvelisibu with high yield and high purity is achieved, with mild reaction conditions, simple operation, safe and environmentally friendly, and is suitable for industrial production.
Smart Images

Figure BDA0004842815360000011 
Figure BDA0004842815360000021 
Figure BDA0004842815360000061
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of compound synthesis, and in particular to a method for synthesizing duvelisib. Background Art
[0002] Duvelisib is an oral kinase inhibitor targeting phosphoinositide-3-kinase (PI3K). Its generic name is duvelisib. It was developed by Verastem Pharmaceuticals in the United States and approved by the FDA for marketing in September 2018. It is used to treat a variety of relapsed or difficult-to-cure blood cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma. Its trade name is Copiktra. This drug is the first approved dual inhibitor of PI3Kδ and PI3Kγ. In addition, the FDA has authorized accelerated approval for its use in adult patients with relapsed or refractory follicular lymphoma.
[0003] There are few reports on the synthesis of Duvelisib in the literature. Only US202202665637A1, WO2011146882 and CN 102711767A reported similar synthesis methods. The specific route is:
[0004]
[0005] The method uses L-alanine as a raw material, obtains a Weinreb amide intermediate after amino protection and aminolysis reaction, and the amide intermediate undergoes condensation, ring closure and deprotection reaction with 2-chloro-6-methylphenylbenzamide to prepare an 8-chloro-1-oxo-3-aminoethyl-2-phenylisoquinoline intermediate, then the intermediate undergoes nucleophilic substitution with 6-chloro-9-(2-tetrahydro-2H-pyran-2-yl)-9H-purine, and finally deprotection is performed to obtain duvelisib.
[0006] In the second step of the method, expensive HOBt and EDCl are used as condensation agents. The third step condensation reaction needs to be carried out at a temperature below -50°C and under the catalysis of n-butyl lithium and Grignard reagent. The reaction conditions are very harsh and difficult to control. n-butyl lithium is flammable and the process is unsafe. In addition, the yield of this step of condensation reaction is low. Literature reports that the yield of this step is only 17.5%. The stereoselectivity of the fourth step ring-closing reaction is not high. The ratio of the S isomer to the R isomer of the chiral amine obtained after deprotection is 7:1, and D-tartaric acid is needed for further separation. In addition, the 6-chloro-9-(2-tetrahydropyran)-purine used in the fifth step is also not easy to purchase. It needs to be prepared by chlorinating hypoxanthine with more than 10 times the amount of phosphorus oxychloride and then reacting it with dihydropyran for nitrogen protection. The chlorination reaction has a low yield, and the post-treatment of a large excess of phosphorus oxychloride is troublesome and environmentally unfriendly. Therefore, the total yield of the process for preparing duvelixib reported in the literature is very low, some raw materials are not easy to obtain, the reaction conditions are very harsh, difficult to control, unsafe, environmentally unfriendly, and not conducive to industrial production. Summary of the invention
[0007] The purpose of the present invention is to provide a method for synthesizing duvelixibu in view of the defects of the prior art, so as to solve the problems existing in the above-mentioned background technology.
[0008] To achieve the above purpose, the present invention provides the following technical solution, and the specific preparation route is as follows:
[0009]
[0010] The specific steps are:
[0011] Step (1): Compound 2 and dimethyl oxalate undergo a condensation reaction and then a ring-closure reaction to obtain compound 3;
[0012] Step (2): Compound 3 undergoes ester hydrolysis reaction to obtain compound 4;
[0013] Step (3): Compound 4 reacts with acetic anhydride under the action of pyridine to produce compound 5;
[0014] Step (4): Compound 5 undergoes an addition dehydration reaction with (S)-tert-butylsulfonamide under the action of B(OCH2CF3)3 and then undergoes a reduction reaction with a reducing agent to obtain compound 6;
[0015] Step (5): Compound 6 undergoes hydrolysis reaction to obtain compound 7;
[0016] Step (6): Compound 7 reacts with hypoxanthine in the presence of a catalyst, an oxidant and DMF to undergo an amine alkylation reaction to obtain duvelixib.
[0017] Preferably, the reaction temperature in step (4) is 40 to 80°C.
[0018] Preferably, in step (4), the ratio of the amount of compound 5 to (S)-tert-butylsulfonamide and B(OCH2CF3)3 is 1.0:1.0-1.5:1.5-3.0.
[0019] Preferably, in step (4), the reducing agent for the reduction reaction is selected from LiBH4, NaBH4, KBH4, Me4NBH4, BH3.THF or LiAlH4.
[0020] Preferably, in step (6), the catalyst is a copper compound.
[0021] Preferably, the copper compound is selected from CuCl2, CuBr2, CuI2, Cu(OAc)2 or Cu(acac)2.
[0022] Preferably, in step (6), the oxidant is a peroxide.
[0023] Preferably, the peroxide is selected from TBHP (tert-butyl peroxide), DTBP (di-tert-butyl peroxide), CHP (cumyl hydroperoxide), m-CPBA (meta-chloroperbenzoic acid) or BPO (benzoyl peroxide).
[0024] Preferably, the reaction temperature in step (6) is 60 to 120°C.
[0025] Preferably, in step (6), the ratio of the amount of hypoxanthine to compound 7, the oxidant and the catalyst is: 1.0:1.2:1.5-3:0.03-0.08.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] (1) The raw materials used in this method are cheap and readily available, and compound 1 is prepared in six steps, with a high yield in each step;
[0028] (2) The entire reaction process is mild, simple to operate, safe and environmentally friendly;
[0029] (3) The purity of compound 1 prepared by this method can reach more than 99%. DETAILED DESCRIPTION
[0030] The preferred embodiments of the present invention are described in detail below so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making a clearer and more definite definition of the protection scope of the present invention.
[0031] Example 1: Synthesis of Compound 3
[0032] Add 120mmol sodium ethoxide and 100mL ethanol to the reaction bottle and stir to mix evenly. Lower the temperature of the reaction system to 10-15°C, add 100mmol compound 2, stir and react for 0.5h, then drop 110mmol dimethyl oxalate, raise the temperature of the reaction system to reflux after the drop is complete, stir and react for 4h, stop the reaction, evaporate the solvent under reduced pressure, add 100mL distilled water and 100mL ethyl acetate, stir, separate the water layer, wash the water layer twice with 60mL ethyl acetate, combine the ethyl acetate layers, dry with anhydrous Na2SO4, and evaporate the solvent under reduced pressure to obtain a crude product.
[0033] Add 100 mL of 10M hydrochloric acid-methanol solution to the crude product obtained above, stir to dissolve, raise the reaction temperature to reflux, and keep stirring for 3 hours. Stop the reaction, evaporate the solvent and hydrogen chloride under reduced pressure, add 100 mL of ethyl acetate to the residue, stir at room temperature for 0.5 hours, filter the precipitated solid, wash the filter cake with 100 mL of ethyl acetate twice, and dry under reduced pressure to obtain compound 3 with a yield of 87%. The structure is 1 HNMR characterization, 1 H NMR (500MHz, CDCl3) δ: 7.81 (dd, J=15.5, 14.6Hz, 1H), 7.69-7.52 (m, 5H), 7.49-7.32 (m, 2H), 6.87 (s, 1H), 3.71 (s, 3H).
[0034] Example 2: Synthesis of Compound 4
[0035] 50mmol of compound 3 and 150mL of 2M NaOH solution were added to the reaction bottle, stirred and mixed evenly, and then the temperature of the reaction system was raised to 40°C and stirred and reacted. After TLC (developing solvent: DCM: MeOH = 6: 1) monitored the reaction to be complete, 100mL of ethanol was added, stirred for 10min, cooled to room temperature, and then the pH was adjusted to 3-4 with 6M hydrochloric acid, stirred for 30min, and the precipitated solid was filtered and dried to obtain compound 4 with a yield of 93%. The structure is shown in FIG. 1 H NMR characterization, 1 H NMR (500MHz, CDCl3) δ: 7.82 (t, J = 7.5Hz, 1H), 7.58 (d, J = 5.0Hz, 5H), 7.54-7.30 (m, 2H), 6.93 (s, 1H).
[0036] Example 3: Synthesis of Compound 5
[0037] Add 50mmol of compound 4, 40mL of pyridine and 25mL of acetic anhydride to the reaction bottle and stir to mix evenly. Raise the system temperature to 75-80℃, and stir the reaction at this temperature for 5h, stop heating, evaporate the solvent under reduced pressure, add 60mL of xylene three times, and then distill to dryness under reduced pressure. Add saturated sodium bicarbonate solution to the residue to adjust the pH to 6-7, extract with 150mL of ethyl acetate twice, combine the organic layers, dry over anhydrous Na2SO4, and evaporate the solvent under reduced pressure to obtain compound 5 with a yield of 79%. The structure is 1 HNMR characterization, 1 H NMR (500MHz, CDCl3) δ: 7.84 (t, J = 7.5Hz, 1H), 7.73-7.56 (m, 5H), 7.49-7.32 (m, 2H), 6.96 (s, 1H), 2.23 (s, 3H).
[0038] Example 4: Synthesis of Compound 6
[0039] Under N2 protection, 50mmol of compound 5, 50mmol of (S)-tert-butylsulfonamide, and 50mL of THF were added to the reaction bottle in sequence. After stirring and mixing, 75mmol of B(OCH2CF3)3 was added dropwise. After the addition was complete, the temperature of the reaction system was raised to 60°C, and the mixture was stirred and reacted for 12h. The reaction was stopped, 100mL of ethyl acetate was added, and then washed with 30mL of saturated sodium bicarbonate solution and 30mL of water, respectively, and the organic layer was separated. The aqueous layer was extracted twice with 100mL of ethyl acetate, and the organic layers were combined, dried with anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain a crude solid. 50mL of methyl tert-butyl ether was added to the crude solid, and after stirring, 200mL of petroleum ether was added to slurry, and filtered to obtain a solid. Add 50mL of THF / H2O (98:2) mixed solution to the obtained solid, lower the temperature to -10 to 0°C, add 150mmol of NaBH4 in three times with stirring, slowly raise the reaction temperature to room temperature after the addition, and keep stirring for 3h. Evaporate the solvent under reduced pressure, add 100mL of dichloromethane to the residue, dry it with anhydrous sodium sulfate, and concentrate it to dryness under reduced pressure, add 50mL of petroleum ether to the residue, heat it to reflux, stop heating, cool it to room temperature, filter the precipitated solid, and dry it to obtain compound 6 with a yield of 60% and an ee value of 96.7%. The compound structure was determined by MS and 1 H NMR confirmed. ESI-LRMS m / z:419.2[M+H] + , 1H NMR(500MHz, CDCl3)δ:7.75-7.52(m,4H),7.51-7.40(m,2H),7.39-7.26(m,2H),6.34(d,J= 2.0Hz, 1H), 5.64 (s, 1H), 5.35 (dd, J = 12.1, 2.0Hz, 1H), 1.46 (s, 9H), 1.25 (d, J = 12.2Hz, 3H).
[0040] Example 5: Synthesis of Compound 6
[0041] Under N2 protection, 50mmol of compound 5, 65mmol of (S)-tert-butylsulfonamide, and 50mL of THF were added to the reaction bottle in sequence, stirred and mixed evenly, and then 100mmol of B(OCH2CF3)3 was added dropwise. After the addition was complete, the temperature of the reaction system was raised to 60°C, and the reaction was stirred and reacted for 12 hours. The subsequent reaction and operation were the same as in Example 4, and compound 6 was obtained after drying, with a yield of 72% and an ee value of 97.9%.
[0042] Example 6: Synthesis of Compound 6
[0043] Under N2 protection, 50mmol of compound 5, 75mmol of (S)-tert-butylsulfonamide, and 50mL of THF were added to the reaction bottle in sequence, stirred and mixed evenly, and then 150mmol of B(OCH2CF3)3 was added dropwise. After the addition was complete, the temperature of the reaction system was raised to 60°C, and the reaction was stirred and kept warm for 12 hours. The subsequent reaction and operation were the same as in Example 4, and compound 6 was obtained after drying, with a yield of 81% and an ee value of 98.9%.
[0044] On the basis of the reaction conditions of Example 6 (i.e., the molar ratio of compound 5, (S)-tert-butylsulfonamide and B(OCH2CF3)3 is 1:1.5:3.0), the reducing agent NaBH4 in the reaction can be replaced by LiBH4, KBH4, Me4NBH4, BH3.THF, LiAlH4, etc.; the temperature of the addition dehydration reaction can be adjusted between 40 and 80°C; other reaction conditions remain unchanged. Some experimental results are shown in Table 1.
[0045] Table 1: Conditions and results of preparing compound 6 in Examples 7 to 13
[0046]
[0047]
[0048] Example 14: Synthesis of Compound 7
[0049] Under N2 protection, 50mmol of compound 6 prepared in Example 6 and 100mL of THF were added to the reaction bottle, stirred and mixed, and then 100mmol of aluminum chloride was added. After stirring and mixing, the temperature of the reaction system was raised to 40°C, and the reaction was stirred and reacted for 3 hours. The heating was stopped, and the reaction mixture was poured into 150mL of ice water with stirring, extracted with 200mL of ethyl acetate three times, the organic layers were combined, ammonia water was added, the pH was adjusted to 8-9, the organic phase was separated, the aqueous phase was extracted with 100mL of ethyl acetate twice, the organic layers were combined, dried, and the solvent was evaporated under reduced pressure to obtain a crude solid. 50mL of isopropanol was added to the crude solid, and 200mL of petroleum ether was added to the slurry after stirring. The precipitated solid was filtered and dried to obtain compound 7 with a yield of 90% and an ee value of 99.2%. The structure was determined by MS and 1 HNMR confirmed. ESI-LRMS m / z: 299.2 [M+H] + , 1 H NMR(500MHz, CDCl3)δ:7.77-7.54(m,4H),7.51-7.39(m,2H),7.32~7.19(m,2H),6.59(d ,J=2.0Hz,1H),4.73(q,J=12.3,1H),1.98(s,1H),1.65(s,1H),1.27(d,J=12.2Hz,3H).
[0050] Example 15: Synthesis of Duvelixibu
[0051] 60mmol of compound 7, 50mmol of hypoxanthine, 150mmol of DTBP, 2.5mmol of Cu(acac)2 and 300mL of DMF were added to the reaction bottle in sequence, and the temperature of the reaction system was raised to 110°C and stirred for 12h. The reaction was stopped, and the reaction solution was cooled to room temperature and then saturated sodium carbonate solution was added to adjust the pH to about 8. The solution was extracted with 200mL of ethyl acetate three times, and the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. 50mL of ethyl acetate and 200mL of petroleum ether were added to the residue, and the mixture was stirred at room temperature for 0.5h. The precipitated solid was filtered and dried to obtain Duvelisib with a yield of 89% and a purity of 99.2%. The structure was determined by MS and 1 H NMR characterization, ESI-LRMS m / z: 417.2 [M+H] + , 1H NMR(500MHz, CDCl3)δ:9.30(s,1H),8.24(s,1H),7.83(s,1H),7.68-7.51(m,4H),7.49-7.38(m, 2H),7.33-7.21(m,2H),6.46(s,1H),5.65(q,J=3.9Hz,1H),3.84(s,1H),1.38(d,J=3.9Hz,3H).
[0052] Example 16: Synthesis of Duvelixibu
[0053] 60mmol of compound 7, 50mmol of hypoxanthine, 75mmol of DTBP, 1.5mmol of Cu(acac)2 and 300mL of DMF were added to the reaction flask in sequence, the temperature of the reaction system was raised to 110°C and stirred for 12h. The post-treatment operation was the same as in Example 15, with a yield of 68% and a purity of 97.7%.
[0054] Example 17: Synthesis of Duvelixibu
[0055] 60mmol of compound 7, 50mmol of hypoxanthine, 150mmol of DTBP, 4.0mmol of Cu(acac)2 and 300mL of DMF were added to the reaction flask in sequence, the temperature of the reaction system was raised to 110°C and stirred for 12h. The post-treatment operation was the same as in Example 15, with a yield of 90% and a purity of 99%.
[0056] Example 18: Synthesis of Duvelixibu
[0057] 60mmol of compound 7, 50mmol of hypoxanthine, 100mmol of DTBP, 2.5mmol of Cu(acac)2 and 300mL of DMF were added to the reaction flask in sequence, the temperature of the reaction system was raised to 110°C and stirred for 12h. The post-treatment operation was the same as in Example 15, with a yield of 81% and a purity of 98.9%.
[0058] On the basis of the reaction conditions of Example 15 (i.e., the molar ratio of hypoxanthine, compound 7, oxidant and catalyst is 1:1.2:3:0.05), the oxidant DTBP in the reaction can be replaced by TBHP, CHP, m-CPBA, BPO; the temperature of the reaction system can be adjusted between 60°C and 120°C; the catalyst Cu(acac)2 in the reaction can be replaced by CuCl2, CuBr2, CuI2, Cu(OAc)2, and other reaction conditions remain unchanged. Some experimental results are shown in Table 2.
[0059] Table 2: Conditions and results for preparing Duvelisib in Examples 19 to 30
[0060]
[0061]
[0062] The above embodiments only express the implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.
Claims
1. A method for synthesizing duvelixibu, characterized in that: The specific preparation route is as follows: The specific steps are: Step (1): Compound 2 and dimethyl oxalate undergo a condensation reaction and then a ring-closure reaction to obtain compound 3; Step (2): Compound 3 undergoes ester hydrolysis reaction to obtain compound 4; Step (3): Compound 4 reacts with acetic anhydride under the action of pyridine to produce compound 5; Step (4): Compound 5 undergoes an addition dehydration reaction with (S)-tert-butylsulfonamide under the action of B(OCH2CF3)3 and then undergoes a reduction reaction with a reducing agent to obtain compound 6; The reducing agent is selected from LiBH4, NaBH4, KBH4, Me4NBH4, BH3.THF or LiAlH4; Step (5): Compound 6 undergoes hydrolysis reaction to obtain compound 7; Step (6): Compound 7 reacts with hypoxanthine in the presence of a catalyst, an oxidant and DMF to undergo an amine alkylation reaction to obtain duvelisib; The catalyst is selected from CuCl2, CuBr2, CuI2, Cu(OAc)2 or Cu(acac)2; the oxidant is selected from TBHP, DTBP, CHP, m-CPBA or BPO.
2. The method for synthesizing duvelixibu according to claim 1, characterized in that: In step (4), the temperature of the addition dehydration reaction is 40 to 80°C.
3. The method for synthesizing duvelixibu according to claim 1, characterized in that: In step (4), the ratio of the amount of compound 5 to (S)-tert-butylsulfonamide and B(OCH2CF3)3 is 1.0:1.0~1.5:1.5~3.
0.
4. The method for synthesizing duvelixibu according to claim 1, characterized in that: The reaction temperature in step (6) is 60-120°C.
5. The method for synthesizing duvelixibu according to claim 1, characterized in that: In step (6), the ratio of the amount of hypoxanthine to compound 7, the oxidant and the catalyst substance is: 1.0:1.2:1.5-3:0.03-0.08.
